# US 12,109,020 B2 · System and method for non-invasive monitoring of advanced glycation end-products (AGE) > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,109,020 B2 - Document ID: US12109020B2 - Status: Granted - Kind: B2 - Application number: 17/365,719 - Filed: 2021-07-01 - Published: 2021-10-21 - Granted: 2024-10-08 - Earliest claimed: 2018-01-09 - Assignees: Medtronic Monitoring, Inc. - Applicants: Medtronic Monitoring, Inc. - Inventors: Rodolphe Katra - Web page: https://patentgrep.com/patent/US12109020B2 ## CPC - A61B 5/1455: using optical sensors, e.g. spectral photometrical oximeters - A61B 5/0071: {by measuring fluorescence emission} - A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement} - G01N 27/3271: {Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood (amperometry per se G01N27/49; aspects concerning the enzyme reagent C12Q1/001)} - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A method of non-invasively monitoring advanced glycation end-product (AGE) concentrations includes providing incident light to patient tissue at one or more excitation wavelengths and monitoring the one or more emission responses at one or more emission wavelengths. Based on the emission responses monitored, a ratio is calculated based on a ratio of the first emission response to the second emission response. ## Claims ### Claim 1 A system comprising: a medical device comprising: a light emitter configured to provide incident light to tissue of a patient at one excitation wavelength; at least one photodetector configured to monitor an emission response to the incident light at a first emission wavelength and at a second emission wavelength; and one or more processors configured to: determine a concentration of an advanced glycation end-product (AGE) based on a ratio of the emission response at the first emission wavelength to the emission response at the second emission wavelength, wherein the emission response at the first emission wavelength is associated with a maximum of the emission response and the emission response at the second emission wavelength is associated with a minimum of the emission response; compare the determined concentration to a threshold; and generate an alert based on the comparison. ### Claim 2 (depends on 1) The system of claim 1, wherein the AGE is glycated hemoglobin (HbA1c). ### Claim 3 (depends on 2) The system of claim 2, wherein the one or more processors are configured to determine a risk of diabetes based on the determined concentration of HbA1c. ### Claim 4 (depends on 1) The system of claim 1, wherein the at least one photodetector is configured to monitor an autofluorescence decay of the emission response at the first emission wavelength and the emission response at the second emission wavelength. ### Claim 5 (depends on 4) The system of claim 4, wherein the at least one photodetector is configured to measure a first rate of decay of the emission response at the first emission wavelength and a second rate of decay of the emission response at the second emission wavelength, and the one or more processors are configured to determine the concentration of the AGE based on a ratio of the first rate of decay to the second rate of decay. ### Claim 6 (depends on 1) The system of claim 1, wherein the at least one photodetector is configured to monitor a first amplitude at the first emission wavelength and a second amplitude at the second emission wavelength. ### Claim 7 (depends on 1) The system of claim 1, wherein the one or more processors comprises a processor of the medical device. ### Claim 8 (depends on 1) The system of claim 1, wherein the medical device is configured for implantation in the patient. ### Claim 9 A method performed by a medical device comprising processing circuitry and being configured to determine a concentration of an advanced glycation end-product (AGE), the method comprising: providing incident light, by a light emitter of the medical device, to tissue of a patient at one excitation wavelength; monitoring, by at least one photodetector of the medical device, an emission response to the incident light at a first emission wavelength and at a second emission wavelength; determining, by the processing circuitry, a concentration of the AGE based on a ratio of the emission response at the first emission wavelength to the emission response at the second emission wavelength, wherein the emission response at the first emission wavelength is associated with a maximum of the emission response and the emission response at the second emission wavelength is associated with a minimum of the emission response; comparing, by the processing circuitry, the determined concentration to a threshold; and generating, by the processing circuitry, an alert based on the comparison. ### Claim 10 (depends on 9) The method of claim 9, wherein the AGE is glycated hemoglobin (HbA1c). ### Claim 11 (depends on 10) The method of claim 10, further comprising determining, by the processing circuitry, a risk of diabetes based on the determined concentration of HbA1c. ### Claim 12 (depends on 9) The method of claim 9, wherein monitoring the emission response comprises monitoring an autofluorescence decay of the emission response at the first emission wavelength and the emission response at the second emission wavelength. ### Claim 13 (depends on 12) The method of claim 12, wherein monitoring the autofluorescence decay comprises measuring a first rate of decay of the emission response at the first emission wavelength and a second rate of decay of the emission response at the second emission wavelength, and wherein determining the concentration of the AGE comprises calculating the concentration of the AGE based on a ratio of the first rate of decay to the second rate of decay. ### Claim 14 (depends on 9) The method of claim 9, wherein monitoring the emission response comprises monitoring a first amplitude at the first emission wavelength and a second amplitude at the second emission wavelength. ### Claim 15 (depends on 9) The method of claim 9, wherein providing the incident light and monitoring the emission response comprises providing the incident light and monitoring the emission response with the medical device implanted in the patient. ### Claim 16 (depends on 9) The method of claim 9, wherein providing the incident light and monitoring the emission response comprises providing the incident light and monitoring the emission response with the medical device subcutaneously inserted in the patient. ### Claim 17 A system comprising: a medical device comprising: a light emitter configured to provide incident light to tissue of a patient at one excitation wavelength; at least one photodetector configured to monitor a first rate of autofluorescence decay of an emission response to the incident light at a first emission wavelength and a second rate of autofluorescence decay of the emission response at a second emission wavelength; and one or more processors configured to: determine a concentration of an advanced glycation end-product (AGE) based on a ratio of the first rate of autofluorescence decay of the emission response at the first emission wavelength to the second rate of autofluorescence decay of the emission response at the second emission wavelength. ### Claim 18 (depends on 17) The system of claim 17, wherein the AGE is glycated hemoglobin (HbA1c).